Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report (2006)
Chapter: Appendix C: Workshop Agenda and Participant List
Appendix C
Workshop Agenda and Participant List
November 1-2, 2005
Keck Center of the National Academies
500 Fifth Street, N.W. • Washington, D.C.
AGENDA
Tuesday, November 1, 2005
|
8:00 a.m. |
Continental Breakfast |
|
8:30 a.m. |
Committee orientation (closed session) |
|
9:00 a.m. |
Workshop convocation and introductions − Samuel Katz, chairman |
|
9:30 a.m. |
Polio eradication plan update Looking ahead to the end-game: Bruce Aylward Strategies for the OPV cessation era: Roland Sutter Potential roles for an antiviral: Mark Pallansch |
|
10:15 a.m. |
Overview of poliovirus biology and pathogenesis Eckard Wimmer |
|
10:45 a.m. |
Coffee Break |
|
11:00 a.m. |
Introduction to potential targets Mutagenesis and RNAi: Raul Andino Capsid-binding compounds: Marc Collett Exploiting dominant inhibition: Karla Kirkegaard Protease inhibitors: Amy Patick |
|
12:00 p.m. |
Organization of afternoon breakout sessions |
|
12:30 p.m. |
Buffet Lunch |
|
1:30 p.m. |
Breakout sessions |
|
3:30 p.m. |
Coffee Break |
|
3:45 p.m. |
Reports on breakout sessions and discussion |
|
5:30 p.m. |
Adjourn |
Wednesday, November 2, 2005
|
8:00 a.m. |
Continental Breakfast |
|
8:30 a.m. |
Organization of day 2 breakout groups |
|
9:00 a.m. |
Working breakout group discussions 1. Public Health group: How would the drug be used in eradication? Who would patients be, how would they be identified and reached? What would be the advantages and disadvantages of the potential compounds identified in day 1 for different aspects of eradication? 2. Biology group: Evaluate each of the potential antivirals: how difficult would each be to develop, how likely to elicit resistance, how long would it take to develop, what would be its possible safety issues? 3. Development group: How much would each type of antiviral cost to develop? How hard might it be to move them |
|
|
through the approval process? Who might develop them? What are the likely timelines involved for each? What are possible sources of funding? |
|
10:30 a.m. |
Coffee Break |
|
10:45 a.m. |
Report from breakout group 1 and discussion |
|
11:30 p.m. |
Report from breakout group 2 and discussion |
|
12:15 p.m. |
Lunch |
|
1:15 p.m. |
Report from breakout group 3 and discussion |
|
2:00 p.m. |
Wrap-up: Designing and filling in a decision matrix for each compound |
|
4:00 p.m. |
Adjourn |
PARTICIPANT LIST
Jim Alexander, CDC
Bruce Aylward, WHO
Debra Birnkrant, Center for Drug Evaluation and Research, FDA
Craig Cameron, Pennsylvania State University
Marc Collett, ViroDefense, Inc.
Walter Dowdle, The Task Force for Child Survival and Development
Ellie Ehrenfeld, NIAID, NIH
Diane Griffin, Johns Hopkins Bloomberg School of Public Health
Matthias Gromeier, Duke University Medical Center
Neal Halsey, Johns Hopkins Bloomberg School of Public Health
Stephen Hughes, National Cancer Institute
Kristin Kenyan, CDC
Karla Kirkegaard, Stanford University School of Medicine
Mauricio Landaverde, Pan American Health Organization
Catherine Laughlin, NIAID, NIH
Mark McKinlay, Gentara Corporation
Philip Minor, National Institute for Biological Standards and Control, UK
Akhter Molla, Abbott Laboratories
Mark Pallansch, CDC
Amy Patick, Pfizer
Olve Peersen, Colorado State University
Jane Seward, CDC
Tim Skern, Medical University of Vienna
Roland Sutter, WHO
Kimberly Thompson, Harvard School of Public Health
Linda Venczel, CDC
Margie Watkins, CDC
Jerry Winkelstein, Johns Hopkins Children’s Center
Peter Wright, Vanderbilt University School of Medicine
Staff from the National Academies Board on Life Sciences
Ann Reid, Study Director
Anne Jurkowski, Program Assistant
Fran Sharples, Director, Board on Life Sciences
